146 related articles for article (PubMed ID: 28347660)
21. Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6.
Song M; Hong M; Lee MY; Jee JG; Lee YM; Bae JS; Jeong TC; Lee S
Food Chem Toxicol; 2013 Sep; 59():549-53. PubMed ID: 23835282
[TBL] [Abstract][Full Text] [Related]
22. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
23. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
24. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels in vitro and in vivo: cyp2d6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling.
Zhu W; Mantione KJ; Shen L; Cadet P; Esch T; Goumon Y; Bianchi E; Sonetti D; Stefano GB
Med Sci Monit; 2005 Nov; 11(11):BR397-404. PubMed ID: 16258388
[TBL] [Abstract][Full Text] [Related]
26. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
27. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
[TBL] [Abstract][Full Text] [Related]
28. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.
DeVane CL; Markowitz JS; Carson SW; Boulton DW; Gill HS; Nahas Z; Risch SC
J Clin Psychopharmacol; 2000 Jun; 20(3):347-9. PubMed ID: 10831022
[TBL] [Abstract][Full Text] [Related]
29. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.
McLaughlin LA; Paine MJ; Kemp CA; Maréchal JD; Flanagan JU; Ward CJ; Sutcliffe MJ; Roberts GC; Wolf CR
J Biol Chem; 2005 Nov; 280(46):38617-24. PubMed ID: 16162505
[TBL] [Abstract][Full Text] [Related]
30. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
Tyndale RF; Sunahara R; Inaba T; Kalow W; Gonzalez FJ; Niznik HB
Mol Pharmacol; 1991 Jul; 40(1):63-8. PubMed ID: 1857341
[TBL] [Abstract][Full Text] [Related]
31. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
Venhorst J; ter Laak AM; Commandeur JN; Funae Y; Hiroi T; Vermeulen NP
J Med Chem; 2003 Jan; 46(1):74-86. PubMed ID: 12502361
[TBL] [Abstract][Full Text] [Related]
32. Double site saturation mutagenesis of the human cytochrome P450 2D6 results in regioselective steroid hydroxylation.
Geier M; Braun A; Fladischer P; Stepniak P; Rudroff F; Hametner C; Mihovilovic MD; Glieder A
FEBS J; 2013 Jul; 280(13):3094-108. PubMed ID: 23552177
[TBL] [Abstract][Full Text] [Related]
33. The effect of dimethyl sulfoxide on the function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with NADPH-cytochrome P450 reductase.
Narimatsu S; Takatsu N; Yamano S; Inoue Y; Hanioka N; Kiryu K; Naito S; Gonzalez FJ; Yamamoto S
Chem Biol Interact; 2006 Jan; 159(1):47-57. PubMed ID: 16214121
[TBL] [Abstract][Full Text] [Related]
34. Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum, Is a CYP2D6 inhibitor of human, monkey, and dog isoforms.
Sun J; Peng Y; Wu H; Zhang X; Zhong Y; Xiao Y; Zhang F; Qi H; Shang L; Zhu J; Sun Y; Liu K; Liu J; A J; Ho RJ; Wang G
Drug Metab Dispos; 2015 May; 43(5):713-24. PubMed ID: 25681130
[TBL] [Abstract][Full Text] [Related]
35. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK
Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
38. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 mediates dopamine formation in the brain in vivo.
Bromek E; Haduch A; Gołembiowska K; Daniel WA
J Neurochem; 2011 Sep; 118(5):806-15. PubMed ID: 21651557
[TBL] [Abstract][Full Text] [Related]
40. Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris.
Dietrich M; Grundmann L; Kurr K; Valinotto L; Saussele T; Schmid RD; Lange S
Chembiochem; 2005 Nov; 6(11):2014-22. PubMed ID: 16222729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
